Structural highlights
Publication Abstract from PubMed
Inhibitors with a new mechanism of action are needed for 20S proteasome (CP) inhibition owing to the ineffectiveness of current market drugs against some types of solid tumors. A novel class of nonpeptidic CP inhibitors has been developed, which display reversible and noncovalent binding. The structure-based design of these highly active and site-specific inhibitors revealed unexplored binding subpockets.
Hydroxyureas as Noncovalent Proteasome Inhibitors.,Gallastegui N, Beck P, Arciniega M, Huber R, Hillebrand S, Groll M Angew Chem Int Ed Engl. 2011 Nov 21. doi: 10.1002/anie.201106010. PMID:22105886[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Gallastegui N, Beck P, Arciniega M, Huber R, Hillebrand S, Groll M. Hydroxyureas as Noncovalent Proteasome Inhibitors. Angew Chem Int Ed Engl. 2011 Nov 21. doi: 10.1002/anie.201106010. PMID:22105886 doi:10.1002/anie.201106010
